Skip to content

Advertisement

  • Poster presentation
  • Open Access

HPV vaccination in HIV+ adolescents and young adults induces strong HPV-specific immune responses

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
BMC Infectious Diseases201414(Suppl 2):P93

https://doi.org/10.1186/1471-2334-14-S2-P93

Published: 23 May 2014

Keywords

  • Cell Mediate Immunity
  • Undetectable Viremia

Background

HPV-associated ano-genital infections represent the most common sexually-transmitted disease in the general population. The incidence of HPV-associated cancers has been increasing in HIV-infected patients. HPV vaccination may be an approach to reduce the risk of HPV-associated cancers in HIV-infected patients and a combined strategy of screening and vaccination may guarantee an adequate prevention of HPV-associated lesions. Immunogenicity of HPV vaccines in HIV-infected patients is still not adequately evaluated. We analyzed immunogenicity of a quadrivalent HPV vaccine in HIV-infected patients without molecular evidence of vaccine-type HPV infection focusing on HPV-specific cell mediated immunity (CMI).

Methodology

31 ARV-treated HIV-infected adolescents (age range 28-14 years, with undetectable viremia and effective CD4 recovery) and 25 sex- and age-matched HIV-seronegative healthy controls were enrolled in the study. HPV-16/18/6/11 VLP vaccine (Gardasil®) was administered 3 times (baseline, 2 and 6 months). Immune activation (CD4/CD25/HLADRII, CD8/CD25/HLADRII), T-cell patterns and HPV-specific immune responses (CD4/IFN-γ/IL-2, CD8/IFN-γ/TNF-α, CD8/Perforin/GranzymeB) were evaluated.

Results

HIV-infected individuals showed: 1) no changes in CD4 counts, percentage of CD4 cells and HIV viral load; 2) a significant increase in naїve CD8 T-cells, activated CD8 T-cells and in central memory CD4 and CD8 T-cells; 3) a significant reduction in terminally differentiated CD8 T-cells; 4) a significant increase in unstimulated and in HPV-specific IL2+/CD4+, IFN-γ+/CD4+, IFN-γ+/CD8+ and TNF-α+/CD8+ T-cells; and 5) a significant increase in HPV-specific Perforin- and Granzyme B-secreting CD8 T-cells. Results obtained in HIV-infected patients were comparable to those seen in HC.

Conclusions

HPV-16/18/6/11 VLP vaccine induces strong HPV-specific cell-mediated immunity in ARV-treated HIV-infected individuals that are comparable to those observed in HIV-seronegative controls. HPV-specific CMI is likely an important component of the protective effect of this vaccine, data herein indicating that this arm of immunity is not impaired in ARV-treated HIV infected individuals.

Authors’ Affiliations

(1)
University of Milan, Chair of Immunology, Milan, Italy

Copyright

© Rainone et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement